Clinical Research Directory
Browse clinical research sites, groups, and studies.
PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis
Sponsor: Washington University School of Medicine
Summary
This observational study will evaluate the imaging performance of the investigational positron emission tomography (PET) radiotracer\[18F\]Fluselenamyl (FSA) in individuals with cardiac amyloidosis. The study aims to determine whether \[18F\]Fluselenamyl PET imaging can detect and characterize amyloid deposits in the heart. Participants will undergo PET imaging following administration of \[18F\]Fluselenamyl, along with clinical assessments and other study procedures as needed. Imaging results will be used to assess tracer uptake in the heart and to evaluate the potential of \[18F\]Fluselenamyl as a noninvasive tool for detecting cardiac amyloidosis. The study will also collect safety information, including clinical assessments, laboratory testing, and monitoring for adverse events. This research may help establish \[18F\]Fluselenamyl as a novel imaging biomarker for cardiac amyloidosis.
Official title: [18F]-Fluselenamyl PET Imaging for Cardiac Amyloidosis (FSA-CA)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-01-14
Completion Date
2030-12
Last Updated
2026-08-18
Healthy Volunteers
No
Conditions
Interventions
[18F]Fluselenamyl (FSA)
Participants will receive a single intravenous administration of the investigational PET radiotracer\[18F\]Fluselenamyl (FSA) followed by positron emission tomography (PET) imaging to evaluate myocardial amyloid deposition and assess the imaging characteristics of the radiotracer in cardiac amyloidosis. The study will also collect safety data, including monitoring for adverse events and clinical assessments
Locations (1)
Washington University in St. Louis
St Louis, Missouri, United States